Kronos Bio (KRON) Competitors $0.95 -0.01 (-0.64%) As of 01/13/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends KRON vs. DMAC, ZNTL, SLN, PROC, CMPX, MGNX, NLTX, AMRN, OPT, and PRQRShould you be buying Kronos Bio stock or one of its competitors? The main competitors of Kronos Bio include DiaMedica Therapeutics (DMAC), Zentalis Pharmaceuticals (ZNTL), Silence Therapeutics (SLN), Procaps Group (PROC), Compass Therapeutics (CMPX), MacroGenics (MGNX), Neoleukin Therapeutics (NLTX), Amarin (AMRN), Opthea (OPT), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry. Kronos Bio vs. DiaMedica Therapeutics Zentalis Pharmaceuticals Silence Therapeutics Procaps Group Compass Therapeutics MacroGenics Neoleukin Therapeutics Amarin Opthea ProQR Therapeutics Kronos Bio (NASDAQ:KRON) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, community ranking, profitability, media sentiment and institutional ownership. Is KRON or DMAC more profitable? DiaMedica Therapeutics has a net margin of 0.00% compared to Kronos Bio's net margin of -867.66%. DiaMedica Therapeutics' return on equity of -43.67% beat Kronos Bio's return on equity.Company Net Margins Return on Equity Return on Assets Kronos Bio-867.66% -64.55% -48.18% DiaMedica Therapeutics N/A -43.67%-40.81% Does the media favor KRON or DMAC? In the previous week, Kronos Bio had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 4 mentions for Kronos Bio and 3 mentions for DiaMedica Therapeutics. Kronos Bio's average media sentiment score of 0.88 beat DiaMedica Therapeutics' score of 0.82 indicating that Kronos Bio is being referred to more favorably in the media. Company Overall Sentiment Kronos Bio Positive DiaMedica Therapeutics Positive Which has stronger earnings & valuation, KRON or DMAC? DiaMedica Therapeutics has lower revenue, but higher earnings than Kronos Bio. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Kronos Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKronos Bio$9.86M5.81-$112.67M-$1.43-0.66DiaMedica TherapeuticsN/AN/A-$19.38M-$0.56-8.86 Which has more volatility & risk, KRON or DMAC? Kronos Bio has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Do insiders and institutionals hold more shares of KRON or DMAC? 64.1% of Kronos Bio shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 24.4% of Kronos Bio shares are owned by company insiders. Comparatively, 7.2% of DiaMedica Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend KRON or DMAC? Kronos Bio currently has a consensus price target of $1.63, suggesting a potential upside of 71.00%. DiaMedica Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 41.13%. Given Kronos Bio's higher possible upside, analysts plainly believe Kronos Bio is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kronos Bio 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer KRON or DMAC? DiaMedica Therapeutics received 72 more outperform votes than Kronos Bio when rated by MarketBeat users. However, 65.63% of users gave Kronos Bio an outperform vote while only 62.84% of users gave DiaMedica Therapeutics an outperform vote. CompanyUnderperformOutperformKronos BioOutperform Votes2165.63% Underperform Votes1134.38% DiaMedica TherapeuticsOutperform Votes9362.84% Underperform Votes5537.16% SummaryKronos Bio beats DiaMedica Therapeutics on 9 of the 17 factors compared between the two stocks. Get Kronos Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KRON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRON vs. The Competition Export to ExcelMetricKronos BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.71M$6.65B$5.31B$8.83BDividend YieldN/A2.91%5.07%4.00%P/E Ratio-0.6610.2386.5916.80Price / Sales5.81189.071,070.46115.83Price / CashN/A57.6843.2437.79Price / Book0.354.975.094.88Net Income-$112.67M$153.46M$122.01M$228.12M7 Day Performance-5.44%-6.42%-3.79%-3.81%1 Month Performance-3.02%-1.41%0.14%0.01%1 Year Performance-19.47%-3.38%25.24%13.15% Kronos Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRONKronos Bio3.1559 of 5 stars$0.95-0.6%$1.63+71.0%-19.5%$57.71M$9.86M-0.66100Short Interest ↑News CoverageDMACDiaMedica Therapeutics1.7227 of 5 stars$5.47-1.6%$7.00+28.0%+65.9%$233.90MN/A-9.7720Short Interest ↑ZNTLZentalis Pharmaceuticals2.3778 of 5 stars$3.17-2.2%$10.00+215.5%-82.0%$225.91M$40.56M-1.27160Short Interest ↓Gap DownSLNSilence Therapeutics2.762 of 5 stars$7.51+1.6%$57.20+661.7%-66.7%$224.76M$16.25M-4.78100PROCProcaps Group2.1654 of 5 stars$1.97-12.4%N/A-63.8%$222.26M$414.10M3.795,500Short Interest ↓Positive NewsGap UpHigh Trading VolumeCMPXCompass Therapeutics2.8393 of 5 stars$1.60+2.6%$11.80+637.5%+7.7%$220.14M$850,000.00-4.3220Short Interest ↑MGNXMacroGenics3.8419 of 5 stars$3.49+0.9%$7.63+118.5%-70.4%$219.04M$139.77M-2.21430Negative NewsNLTXNeoleukin TherapeuticsN/A$23.23+1.5%N/A-35.0%$218.32MN/A-7.4790Gap DownHigh Trading VolumeAMRNAmarin0.1952 of 5 stars$0.53+0.0%N/A-56.4%$217.08M$241.02M-5.87360Analyst UpgradeAnalyst RevisionNews CoverageOPTOpthea3.1904 of 5 stars$3.69-1.9%$12.00+225.2%+23.9%$215.48M$124,666.000.008PRQRProQR Therapeutics2.6283 of 5 stars$2.63-4.7%$7.60+189.0%+1.8%$214.82M$17.88M-8.22180Short Interest ↑News Coverage Related Companies and Tools Related Companies DMAC Competitors ZNTL Competitors SLN Competitors PROC Competitors CMPX Competitors MGNX Competitors NLTX Competitors AMRN Competitors OPT Competitors PRQR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KRON) was last updated on 1/14/2025 by MarketBeat.com Staff From Our PartnersGreatest crypto bull market in history?A crypto storm is coming Right now, conditions are in place for a historic move we expect will be the great...Stansberry Research | Sponsored$24 trillion tech spotted at Mar-a-Lago?President Trump’s Secret Service was recently spotted using an odd new technology at his home in Mar-a-Lago…Centurion Publishing | SponsoredTrump’s 2nd Term Shocker: New AI ComingForget Nvidia. Legendary investor Louis Navellier is recommending this little-known company because it's he...10 Minute Trades | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Elon Spotted at Weird Facility in Memphis? What Elon Musk is planning at a remote facility in Memphis may be his greatest achievement to date. Because...Paradigm Press | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kronos Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kronos Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
